The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Cullinan Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Daniel A. Vaena
Honoraria - HMP; OncLive; OneOncology
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Immunomedics; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)
 
Oladapo O. Yeku
Stock and Other Ownership Interests - hC Bioscience
Honoraria - Medscape
Consulting or Advisory Role - Gimv; hC Bioscience; TigaTx
Patents, Royalties, Other Intellectual Property - Dr. Yeku has a patent for MUC16 Directed Antibodies for therapeutic applications pending and a patent for Human Artificial Chromosomes for therapeutic applications pending.
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Biogen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Stephanie Gaillard
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Curio Science; Elevar Therapeutics; Elevar Therapeutics; GlaxoSmithKline; Immunogen; Novartis
Research Funding - AstraZeneca (Inst); Compugen (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Sermonix Pharmaceuticals
 
Adeboye H. Adewoye
Employment - Compugen
Leadership - Compugen
Stock and Other Ownership Interests - Compugen
Research Funding - Compugen
Patents, Royalties, Other Intellectual Property - Compugen
Travel, Accommodations, Expenses - Compugen
 
John William Moroney
No Relationships to Disclose